Singapore pharmaceuticals
Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants
The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins
Singapore’s October factory output records highest jump in 15 years, up 29.1% on pharma surge
This surprised private-sector economists who had expected a 6.7% growth
iX Biopharma raises gross proceeds of S$6.7 million from placement
The amount surpasses the goal of S$5 million; new shares issued at S$0.10 apiece
iX Biopharma proposes placement to raise gross proceeds of at least S$5 million as it eyes US expansion
The placement price represents a discount of 9.7% to the volume weighted average price of S$0.1107 per share
iX Biopharma shares jump 35% on potential US, Australia listing plans
This brings the counter up 408% in the year to date
Singapore-based pharma companies waiting for confirmation of US tariff exemptions: MTI
Talks on a preferential tariff arrangement for Singapore’s pharmaceutical exports to the US continue, says Minister of State for Trade and Industry
New US pharmaceutical tariffs may have ‘no immediate impact’ on drugmakers: DPM Gan
Drugmakers are ‘continuing to clarify’ to better understand the conditions and criteria tied to the new taxes
The biopharma scene in Singapore is vibrant, but few make it to SGX
More listings will keep the Republic’s capital markets robust, develop an ecosystem and strengthen its regional hub status
Trump’s pharma tariffs put Singapore at ‘greatest risk’ among major exporters if no exemptions granted: economists
Without exemptions, the effective tariff rate on the Republic’s shipments could exceed 30%, compared with 4% now
Hyphens Pharma bets big on Asean’s medical aesthetics boom
While the group is not exposed to tariff pressures, currency volatility remains a near-term challenge
